A Focus on Antiarrhythmic Properties of Ranolazine
- 6 April 2012
- journal article
- review article
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 17 (4), 353-356
- https://doi.org/10.1177/1074248412442000
Abstract
Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the genesis of transmembrane cardiac action potential. It was initially developed as an antianginal agent but was found to additionally exert antiarrhythmic actions, due to its multichannel-blocking properties. In recent years, several studies about the antiarrhythmic properties of ranolazine were conducted, demonstrating the beneficial effects of this drug in both atrial and ventricular arrhythmias, such as atrial fibrillation, ventricular premature beats, ventricular tachycardia, torsades de pointes, and ventricular fibrillation. Our aim is to briefly review the main points of these studies, most more experimental than clinical.Keywords
This publication has 21 references indexed in Scilit:
- Comparison of Effectiveness and Safety of Ranolazine Versus Amiodarone for Preventing Atrial Fibrillation After Coronary Artery Bypass GraftingThe American Journal of Cardiology, 2011
- Electrophysiologic basis for the antiarrhythmic actions of ranolazineHeart Rhythm, 2011
- Synergistic Effect of the Combination of Ranolazine and Dronedarone to Suppress Atrial FibrillationJournal of the American College of Cardiology, 2010
- Enhanced Late Na+Currents in Atrial Fibrillation: New Drug Target or Just an Epiphenomenon?Journal of the American College of Cardiology, 2010
- Altered Na+Currents in Atrial Fibrillation: Effects of Ranolazine on Arrhythmias and Contractility in Human Atrial MyocardiumJournal of the American College of Cardiology, 2010
- Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?Current Opinion in Cardiology, 2009
- Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparationsHeart Rhythm, 2008
- Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non–ST-Segment–Elevation Acute Coronary SyndromeCirculation, 2007
- Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial FibrillationCirculation, 2007
- Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation Acute Coronary SyndromesThe MERLIN-TIMI 36 Randomized TrialJama-Journal Of The American Medical Association, 2007